Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (October 2014)
18 slides from Oncosil Medical's investor presentation, Oct 16, 2014
Slide 1: OncoSil Medical Investor Update
OncoSil Medical For personal use only October 2014 ASX: OSL Investor Update Dr Roger Aston Executive Chairman
Slide 2: Important Notice
Important Notice For personal use only The purpose of the presentation is to provide an update of the business of OncoSil Medical Ltd (ASX:OSL). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. According
Slide 3: OncoSil - Potential treatment for Pancreatic Cancer
OncoSil™ - Potential treatment for Pancreatic Cancer For personal use only Next Generation Radiotherapy • OncoSil Medical has an implantable nuclear medicine ( radiotherapy) device that has commenced a pivotal study in pancreatic cancer. • Localised radiation therapy is inherently safe, effective an
Slide 4: OncoSil: Radiation therapy delivered to the cancer site
OncoSilTM For personal use only Radiation therapy delivered to the cancer site • Pure beta radiation source (P32) to avoid systemic side effects • Localised radiation therapy using “sticky” microparticles • Carrier particles are inert silicon • Particles are suspended in fluid to allow direct inject
Slide 5: How OncoSil Works
How OncoSilTM Works For personal use only OncoSilTM is suspended in a The physician guides an endoscope down the shielded syringe in the oesophagus, through the stomach and into the first part operating theatre where a of the small intestine. Ultrasound is used to image the physician will make the t
Slide 6: OncoSil Benefits
OncoSilTM Benefits For personal use only • Localised treatment reduces serious side effects associated with standard radiotherapy • Classified as a device therefore shorter time to market than traditional drug development • Synergistic effect with current chemotherapy regime as Abraxane and gemcitab
Slide 7: Medical Device Development
Medical Device Development For personal use only Differences between drug and device development Drugs require Phase I, II and III Devices require Pilot and Pivotal clinical studies studies • Expensive, slow and resource • Faster, fewer patients, no drug intense interaction work • Typically 10 years
Slide 8: Pancreatic Cancer: Unmet Medical Need
Pancreatic Cancer For personal use only Unmet Medical need • 280,000+ pancreatic cancer incidence yearly world wide (1) • Approximately 45,000 new patients diagnosed with pancreatic cancer in the US each year • Poor prognosis -Median survival ~8 months and 5 year survival less than 7% Target Market
Slide 9: Limited Current Pancreatic Cancer Treatments
Limited Current Pancreatic Cancer Treatments For personal use only Surgery: Cut out the tumour: • Only possible in 20% of PC patients Chemotherapy: Poison tumour growth, Examples: • Gemcitabine and Nab-paclitaxel Immune therapy: Disrupt growth pathways in the tumour: Vaccines against tumour antigens
Slide 10: Clinical data to date
Clinical data to date For personal use only Clinical Trial Results • 17 locally advanced pancreatic cancer patients in single arm study • Significant anti-cancer activity – disease control rate of 82% : 4 Partial Responses, 10 Stable disease and 3 Progressive Disease • Average reduction in pain of 35
Slide 11: Global Regulatory Strategy
Global Regulatory Strategy For personal use only Device Registration Plan for Key Pharmaceutical Markets Calendar Yr H2 2014 H1 2015 H2 2015 H1 2016 H2 2016 H1 2017 H2 2017 OncoSil™ Pivotal study IDE FDA CE Marking Sales in EU, Canada & Aus OncoSil’s global registration strategy is with CE (Conformi
Slide 12: Pivotal Trial for FDA approval
Pivotal Trial for FDA approval For personal use only Study Purposes • Achievement of registration for OncoSil™ in USA • Create network of Key Opinion Leaders globally • Establish viable and validated distribution channel for OncoSil™ Study Design • Randomized open label clinical trial (Gold Standard
Slide 13: Pivotal Trial Endpoints
Pivotal Trial For personal use only Endpoints Primary: • Overall survival (time from randomization to death) Secondary: • Progression free survival (time to clinical or radiological confirmed progression) • Quality of Life (EORTC Scale) • Pain (Brief Pain Index, point of time and 24 hours) Challenge
Slide 14: OncoSil Manufacturing
OncoSilTM Manufacturing For personal use only • Mix Silicon and Phosphorus at 1480oC Starting • Atomise with water to create Si-P micro particles material • Grade particles to 30 microns • Etch with acid to create porosity Create 32P • Place in a high neutron reactor Micro particles • Package and sh
Slide 15: Patents, Trademark & Know How
Patents, Trademark & Know How For personal use only • Multiple granted patents in US, EU, Japan and elsewhere for the therapeutic product and for the manufacturing method (2022 - 2024) • Trademark protection granted for OncoSil™ in Australia, New Zealand, UK, EU, USA, Japan and Singapore Know-How, E
Slide 16: Board Management
Board Management Slide For personal use only Executive Chairman: Dr. Roger Aston Non-Executive Director: Mr. Lawrence Gozlan Non-Executive Director: Mr. Martin Rogers Managing Director and CEO: Dr. Neil Frazer Financial Controller & Company Secretary: Mr. Peter Casey Head of EU Operations: Dr. Drew
Slide 17: Capital Structure
Capital Structure For personal use only ASX code OSL Market Cap (October 6, 2014) $A40m Shares on issue 355m Cash (June 30, 2014) $A7m 17
Slide 18: Summary of Investment Profile
Summary of Investment Profile For personal use only Lower Risk • Medical device • Internal radiation – next generation of radiotherapy with other products on market demonstrating clinical efficacy • OncoSil™ has supporting clinical data already Huge Rewards • Pancreatic cancer unmet need • Potential
OncoSil Medical — Investor Presentation (October 2014) on 6ix